Standard BioTools Inc.

NasdaqGS:LAB Stock Report

Market Cap: US$902.6m

Standard BioTools Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Michael Egholm

Chief executive officer

US$16.0m

Total compensation

CEO salary percentage2.3%
CEO tenure2yrs
CEO ownership0.1%
Management average tenureless than a year
Board average tenure1.1yrs

Recent management updates

Recent updates

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Jan 12
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Aug 13
Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Fluidigm Corporation: Investment Opportunity

Jan 26

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Dec 15
Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Jul 27
Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Jun 20

Fluidigm gains after report that activist takes 11% stake, may push for unit sale

May 11

Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation

May 07

CEO Compensation Analysis

How has Michael Egholm's remuneration changed compared to Standard BioTools's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$75m

Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$84m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$16mUS$373k

-US$190m

Compensation vs Market: Michael's total compensation ($USD16.02M) is above average for companies of similar size in the US market ($USD3.44M).

Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.


CEO

Michael Egholm (60 yo)

2yrs

Tenure

US$16,020,093

Compensation

Dr. Michael Egholm, Ph.D. served as the President of Biopharmaceuticals and Senior Vice President at Pall Corporation since July 2014 until January 17, 2017. He serves as Director at Abbratech, Inc. and Ab...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Egholm
President2yrsUS$16.02m0.14%
$ 1.3m
Hanjoon Kim
Chief Operating Officer2yrsUS$5.96m0.055%
$ 498.1k
Jeffrey Black
Chief Financial Officerless than a yearno data0.022%
$ 202.9k
Shane Bowen
Chief Technology Officerless than a yearno datano data
Adam Taich
Chief Strategy Officerless than a yearno datano data

0.9yrs

Average Tenure

53yo

Average Age

Experienced Management: LAB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Egholm
President2yrsUS$16.02m0.14%
$ 1.3m
Fenel Eloi
Independent Director1.1yrsno data0%
$ 0
Franklin Witney
Independent Director2yrsno data0.0091%
$ 82.1k
Kathy Hibbs
Directorless than a yearno datano data
Eli Casdin
Independent Director2yrsUS$274.00k0.027%
$ 244.4k
Thomas Carey
Chairman of the Boardless than a yearno datano data
Troy Cox
Directorless than a yearno data0.023%
$ 205.4k

1.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: LAB's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.